Trial
NCT00109109
A Clinical Trial of Oral Suberoylanilide Hydroxamic Acid (SAHA) in Patients With Advanced Multiple Myeloma (0683-004)
Phase ITERMINATEDOTHER/UNKNOWNConfidence: LOW
Sponsor
Merck Sharp & Dohme LLC
Collaborators
—
Condition
Multiple Myeloma
Intervention
MK0683, vorinostat, Suberoylanilide Hydroxamic Acid (SAHA) / Duration of Treatment - Up to 8 Cycles or 6 months
Why stopped
—
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2019-11-14